However, more research is still needed in direct comparison to semaglutide to confirm the effectiveness of tirzepatide in reducing cardiovascular risks
*Correspondence: Ana Karina Zambrano, [email protected] These authors have contributed equally to this work and share first authorship Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Modifier 25 and CPT 96372: The Complete Rule Modifier 25 belongs on the E/M code, not on 96372
Severe hypoglycemia is a secondary overdose risk, particularly in patients already taking insulin or sulfonylureas
Victoza (liraglutide): A daily GLP-1 with a much shorter half-life of 13 hours, clearing from the system within 2-3 days of stopping
This helps absorption and supports circulation